Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline

Summary: Gilead Sciences is going on a massive shopping spree! They just agreed to pay up to $5 billion to buy a German biotech company named Tubulis. Tubulis makes a special kind of medicine called an ADC, which acts like a "smart bomb" to attack cancer cells without hurting the rest of the body.

Their top new drug has shown amazing results in treating ovarian cancer and lung cancer. Gilead hopes this huge deal will make them a powerhouse in the fight against cancer, turning Tubulis's labs into a major hub for creating new, life-saving treatments.

Source: rssapp-fiercebiotech-com URL: fiercebiotech.com/biotech/gilead-inks-5b-tubulis-buyout-bolster-oncology-adc-pipeline (opens in new tab)